US Government Purchases $56 Million Supply of Smallpox-Mpox Vaccines

Emergent BioSolutions Inc. recently announced that a contract modification has been executed for $56 million to supply ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to the U.S. government.

As of September 9, 2025, deliveries are expected to begin this month.

"Our new contract modification for ACAM2000® vaccine reflects the continued collaboration between Emergent and the U.S. government to prioritize preparedness support," said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent, in a press release.

"With our North American manufacturing and supply chain capabilities at the ready, and Emergent's commitment to being a trusted partner of the U.S. government and offering most favored pricing as part of that commitment, we are helping to strengthen public health efforts through our medical countermeasures portfolio."

This brings the total projected sales for ACAM2000® vaccine and ancillary products to more than $120 million this year from a diverse base of customers. ACAM2000 is licensed for active immunization against smallpox and mpox disease in individuals determined to be at high risk for smallpox or mpox infection.

ACAM2000 was first approved by the U.S. Food and Drug Administration (FDA) in 2007 for active immunization to prevent smallpox disease in individuals determined to be at high risk for smallpox infection. Smallpox has been eradicated in the United States, with no cases occurring since 1977.

The FDA subsequently approved it in August 2024 for immunization against mpox in individuals identified as being at high risk for mpox.

As of September 11, 2025, the FDA has also approved Bavarian Nordic JYNNEOS® vaccine for the prevention of both diseases. Unlike ACAM2000, JYNNEOS is available at various pharmacies and clinics in the U.S.